Printer Friendly

Vaccine development company receives European patent allowance for enhanced immune response.

ImmunoVaccine Technologies, Inc. (Halifax, Canada), a privately held life sciences vaccine development company, received a patent allowance from the European patent office for their patent application entitled 'Vaccines with enhanced immune response and methods for their preparation'. The patent number provided to IVT was 01 983 349.0-2402. All of the claims filed for the patent were allowed following modification of claims 43, 44 and 45. These claims were modified to conform to European patent presentation.

Upon receiving the notification Dr. Warwick Kimmins, President and CEO stated, "The issuance of the European patent complements the US patent protection for our VacciMax vaccine platform technology and is good news for IVT's shareholders and our industry partners."

IVT is best known for its proprietary vaccine enhancement platform, VacciMax. The company has significantly advanced the technology since the company was founded in 2000 by Dr. Kimmins, a former Dalhousie University (Halifax, Canada) Dean of Science. IVT's first product was SpayVac, a contraceptive vaccine effective in many animals. According to Dr. Kimmins, the logical next step for the development of the VacciMax platform was in the area of infectious diseases and cancer.

IVT is currently focused developing its VacciMax platform, through licensing the technology to partner companies, both mid to large size, in the animal and human health sectors.

ImmunoVaccine is a life sciences company focused on commercializing a proprietary vaccine platform, trade named VacciMax. The VacciMax platform results in a more rapid immune response with a higher level and longer duration of antibody levels following a single inoculation while providing multi-year protection without boosting. This patented technology is available under license to reformulate existing commercial vaccines and in support of newly developed vaccines for human and veterinary applications.

ImmunoVaccine Technologies, Inc.

COPYRIGHT 2005 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Sep 1, 2005
Previous Article:Sirna granted patent covering RNAi-mediated inhibition of gene expression.
Next Article:Genetic mutations in brain tumors identified by scientists from Venter Institute, Ludwig Institute, and Johns Hopkins.

Related Articles
Biomira receives United States patent for its Theratope cancer vaccine
European Patent Office affirms validity of claims in Aquila's European patent covering Stimulon technology.
Synergy Vaccines announces issuance of alpha-2-macroglobulin complex patent.
Genetronics and Merck sign licensing agreement for MedPulser(R) DNA delivery system to support DNA vaccine delivery.
Genencor to receive patent for I-MUNE assay technology for reduction or enhancement of immune response.
Stressgen's European patent upheld against Antigenics' challenge.
Carrington receives European patent for stabilization of proteins and peptides.
Iomai awarded key vaccine technology patent.
ImmunoVaccine Broadens Its Enhanced Immune Response Patent Protection to Japan.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters